Ibasunate Softgel Galatin/Molle x9

Ibasunate Softgel is an advanced antimalarial medication combining Dihydroartemisinin (40mg) and Piperaquine Phosphate (320mg) in a convenient softgel formulation. This combination therapy effectively targets Plasmodium parasites that cause malaria, offering rapid relief and sustained protection.

Uses

Ibasunate Softgel treats uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax. It’s also used for malaria prevention in high-risk transmission areas when recommended by healthcare providers. This medication is effective against many drug-resistant strains of malaria parasites.

Benefits

• Combines two potent antimalarial agents for enhanced efficacy
• Rapidly clears malaria parasites from the bloodstream
• Prevents resistance development through dual-drug action
• Offers convenient once-daily dosing for better compliance
• Suitable for adults and children weighing over 5kg
• Provides extended protection due to long half-life
• Demonstrates high cure rates in clinical studies
• Features improved bioavailability in softgel form
• Reduces risk of recrudescence (return of symptoms)

How It Works

Dihydroartemisinin rapidly reduces parasite load by disrupting the parasites’ metabolism through free radical generation and inhibiting their protein synthesis. Piperaquine Phosphate, with its longer half-life, targets remaining parasites and prevents their multiplication, providing sustained protection against recurrence and reinfection.

Dosage

Take Ibasunate Softgel with water at the same time each day, preferably with food to improve absorption and minimize stomach discomfort.

Duration of Action

Ibasunate Softgel begins eliminating parasites within hours after administration. Most patients experience fever reduction within 24-48 hours. Dihydroartemisinin clears most parasites quickly while Piperaquine maintains protective blood levels for 4-5 weeks, preventing recurrence and reinfection.

Side Effects

Common side effects include mild nausea, vomiting, abdominal discomfort, loss of appetite, and dizziness. These typically subside without intervention. Rare but serious effects include allergic reactions, liver or kidney problems, and cardiac rhythm disturbances. Contact your healthcare provider if side effects persist or worsen.

Warning

Complete the full 3-day treatment course even if symptoms improve rapidly. Ibasunate may affect heart rhythm in susceptible individuals. Avoid use in patients with known QT interval prolongation or taking medications that prolong the QT interval. Seek immediate medical attention for severe vomiting, irregular heartbeat, or seizures.

Pregnancy and Breastfeeding

Ibasunate Softgel should not be used during the first trimester of pregnancy unless clearly necessary and no alternatives exist. It may be used in the second and third trimesters if benefits outweigh risks. Limited data exists on safety during breastfeeding; consult your healthcare provider before use.

Interaction

• May increase risk of QT prolongation with antiarrhythmic drugs
• Potential decreased effectiveness with certain anticonvulsants
• Possible interactions with antiretroviral medications
• May reduce effectiveness of hormonal contraceptives
• Caution advised with other medications metabolized by liver enzymes

Precaution

Use with caution in patients with liver or kidney impairment. Monitor patients with cardiac conditions closely. Avoid in patients with previous allergic reactions to artemisinin derivatives. Confirm malaria diagnosis before treatment when possible. Do not exceed recommended dosage as it may increase risk of adverse effects.

Important Information

Ibasunate Softgel is not for preventive treatment in endemic areas without medical advice. Continue using mosquito protection measures during and after treatment. If vomiting occurs within one hour of taking, repeat the dose. Seek medical attention if symptoms persist after completing treatment. Store below 30°C in original packaging, protected from light and moisture.